GENB•Generate Biomedicines is advancing its twice-yearly anti-TSLP antibody GB-0895 through Phase 3 trials in severe asthma. The trials target full enrollment in the second half of 2027 and first half of 2028.
Generate Biomedicines is advancing GB-0895 through the SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials in severe asthma. The trials target full enrollment in the second half of 2027 and first half of 2028.
The company expects Phase 1b results for GB-0895 in moderate-to-severe COPD in the second half of 2026. Its MMAE neutralizer GB-4362 is in Phase 1 development, with results expected in 2027. A collaboration with Zealand Pharma expands its pipeline into obesity through two confidential programs.
